カテゴリー： 世界, 医療/バイオ, LP Information

世界のレニン-アンジオテンシン-システム（RAS）作用剤市場予測 2023年-2029年

【英語タイトル】Global Renin-Angiotensin-System (RAS)-Acting Agent Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC04154）・商品コード：LP23DC04154
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：100
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のレニン-アンジオテンシン-システム（RAS）作用剤市場」は、過去の販売実績から2022年の世界のレニン-アンジオテンシン-システム（RAS）作用剤の総販売量を検討し、2023年から2029年の予測されるレニン-アンジオテンシン-システム（RAS）作用剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のレニン-アンジオテンシン-システム（RAS）作用剤の市場規模を掲載し、XXX百万米ドル規模の世界のレニン-アンジオテンシン-システム（RAS）作用剤市場の詳細な分析を提供します。本インサイトレポートは、世界のレニン-アンジオテンシン-システム（RAS）作用剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のレニン-アンジオテンシン-システム（RAS）作用剤市場における各社の独自のポジションをより深く理解するために、レニン-アンジオテンシン-システム（RAS）作用剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のレニン-アンジオテンシン-システム（RAS）作用剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。レニン-アンジオテンシン-システム（RAS）作用剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。レニン-アンジオテンシン-システム（RAS）作用剤の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。レニン-アンジオテンシン-システム（RAS）作用剤のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

レニン-アンジオテンシン-システム（RAS）作用剤の世界主要メーカーとしては、Novartis AG、 Pfizer, Inc.、 AstraZeneca plc、 Merck & Co., Inc.、 Sanofi S.A.、 Bristol-Myers Squibb Company、 Daiichi Sankyo Company,Limited、 Takeda Pharmaceutical Company Limited、 Boehringer lngelheim GmbH、 Johnson & Johnsonなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のレニン-アンジオテンシン-システム（RAS）作用剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではレニン-アンジオテンシン-システム（RAS）作用剤市場をセグメンテーションし、種類別 (アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）)、用途別 (高血圧、心不全、慢性腎臓病、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）

・用途別区分：高血圧、心不全、慢性腎臓病、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のレニン-アンジオテンシン-システム（RAS）作用剤市場の10年間の市場状況・展望は？
・世界および地域別に見たレニン-アンジオテンシン-システム（RAS）作用剤市場成長の要因は何か？
・レニン-アンジオテンシン-システム（RAS）作用剤の市場機会はエンドマーケットの規模によってどのように変化するのか？
・レニン-アンジオテンシン-システム（RAS）作用剤のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：レニン-アンジオテンシン-システム（RAS）作用剤の年間販売量2018-2029、地域別現状・将来分析
・レニン-アンジオテンシン-システム（RAS）作用剤の種類別セグメント：アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）
・レニン-アンジオテンシン-システム（RAS）作用剤の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・レニン-アンジオテンシン-システム（RAS）作用剤の用途別セグメント：高血圧、心不全、慢性腎臓病、その他
・レニン-アンジオテンシン-システム（RAS）作用剤の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のレニン-アンジオテンシン-システム（RAS）作用剤市場
・企業別のグローバルレニン-アンジオテンシン-システム（RAS）作用剤市場データ：2018-2023年の年間販売量、市場シェア
・企業別のレニン-アンジオテンシン-システム（RAS）作用剤の年間売上：2018-2023年の売上、市場シェア
・企業別のレニン-アンジオテンシン-システム（RAS）作用剤販売価格
・主要企業のレニン-アンジオテンシン-システム（RAS）作用剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

レニン-アンジオテンシン-システム（RAS）作用剤の地域別レビュー
・地域別のレニン-アンジオテンシン-システム（RAS）作用剤市場規模2018-2023：年間販売量、売上
・主要国別のレニン-アンジオテンシン-システム（RAS）作用剤市場規模2018-2023：年間販売量、売上
・南北アメリカのレニン-アンジオテンシン-システム（RAS）作用剤販売の成長
・アジア太平洋のレニン-アンジオテンシン-システム（RAS）作用剤販売の成長
・ヨーロッパのレニン-アンジオテンシン-システム（RAS）作用剤販売の成長
・中東・アフリカのレニン-アンジオテンシン-システム（RAS）作用剤販売の成長

南北アメリカ市場
・南北アメリカの国別のレニン-アンジオテンシン-システム（RAS）作用剤販売量、売上（2018-2023）
・南北アメリカのレニン-アンジオテンシン-システム（RAS）作用剤の種類別販売量
・南北アメリカのレニン-アンジオテンシン-システム（RAS）作用剤の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のレニン-アンジオテンシン-システム（RAS）作用剤販売量、売上（2018-2023）
・アジア太平洋のレニン-アンジオテンシン-システム（RAS）作用剤の種類別販売量
・アジア太平洋のレニン-アンジオテンシン-システム（RAS）作用剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のレニン-アンジオテンシン-システム（RAS）作用剤販売量、売上（2018-2023）
・ヨーロッパのレニン-アンジオテンシン-システム（RAS）作用剤の種類別販売量
・ヨーロッパのレニン-アンジオテンシン-システム（RAS）作用剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のレニン-アンジオテンシン-システム（RAS）作用剤販売量、売上（2018-2023）
・中東・アフリカのレニン-アンジオテンシン-システム（RAS）作用剤の種類別販売量
・中東・アフリカのレニン-アンジオテンシン-システム（RAS）作用剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・レニン-アンジオテンシン-システム（RAS）作用剤の製造コスト構造分析
・レニン-アンジオテンシン-システム（RAS）作用剤の製造プロセス分析
・レニン-アンジオテンシン-システム（RAS）作用剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・レニン-アンジオテンシン-システム（RAS）作用剤の主要なグローバル販売業者
・レニン-アンジオテンシン-システム（RAS）作用剤の主要なグローバル顧客

地域別のレニン-アンジオテンシン-システム（RAS）作用剤市場予測レビュー
・地域別のレニン-アンジオテンシン-システム（RAS）作用剤市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・レニン-アンジオテンシン-システム（RAS）作用剤の種類別市場規模予測
・レニン-アンジオテンシン-システム（RAS）作用剤の用途別市場規模予測

主要企業分析
Novartis AG、 Pfizer, Inc.、 AstraZeneca plc、 Merck & Co., Inc.、 Sanofi S.A.、 Bristol-Myers Squibb Company、 Daiichi Sankyo Company,Limited、 Takeda Pharmaceutical Company Limited、 Boehringer lngelheim GmbH、 Johnson & Johnson
・企業情報
・レニン-アンジオテンシン-システム（RAS）作用剤製品
・レニン-アンジオテンシン-システム（RAS）作用剤販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Renin-Angiotensin-System (RAS)-Acting Agent market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Renin-Angiotensin-System (RAS)-Acting Agent players cover Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company,Limited, Takeda Pharmaceutical Company Limited and Boehringer lngelheim GmbH, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)’ newest research report, the “Renin-Angiotensin-System (RAS)-Acting Agent Industry Forecast” looks at past sales and reviews total world Renin-Angiotensin-System (RAS)-Acting Agent sales in 2022, providing a comprehensive analysis by region and market sector of projected Renin-Angiotensin-System (RAS)-Acting Agent sales for 2023 through 2029. With Renin-Angiotensin-System (RAS)-Acting Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Renin-Angiotensin-System (RAS)-Acting Agent industry.
This Insight Report provides a comprehensive analysis of the global Renin-Angiotensin-System (RAS)-Acting Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Renin-Angiotensin-System (RAS)-Acting Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Renin-Angiotensin-System (RAS)-Acting Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renin-Angiotensin-System (RAS)-Acting Agent and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renin-Angiotensin-System (RAS)-Acting Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Renin-Angiotensin-System (RAS)-Acting Agent market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Angiotensin Converting Enzyme Inhibitors (ACEi)
Angiotensin Receptor Blockers (ARBs)
Segmentation by application
Hypertension
Heart Failure
Chronic Kidney Disease
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Novartis AG
Pfizer, Inc.
AstraZeneca plc
Merck & Co., Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
Daiichi Sankyo Company,Limited
Takeda Pharmaceutical Company Limited
Boehringer lngelheim GmbH
Johnson & Johnson
Key Questions Addressed in this Report
What is the 10-year outlook for the global Renin-Angiotensin-System (RAS)-Acting Agent market?
What factors are driving Renin-Angiotensin-System (RAS)-Acting Agent market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Renin-Angiotensin-System (RAS)-Acting Agent market opportunities vary by end market size?
How does Renin-Angiotensin-System (RAS)-Acting Agent break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Country/Region, 2018, 2022 & 2029
2.2 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type
2.2.1 Angiotensin Converting Enzyme Inhibitors (ACEi)
2.2.2 Angiotensin Receptor Blockers (ARBs)
2.3 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
2.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
2.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Type (2018-2023)
2.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Type (2018-2023)
2.4 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application
2.4.1 Hypertension
2.4.2 Heart Failure
2.4.3 Chronic Kidney Disease
2.4.4 Other
2.5 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
2.5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Market Share by Application (2018-2023)
2.5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Application (2018-2023)
2.5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Application (2018-2023)
3 Global Renin-Angiotensin-System (RAS)-Acting Agent by Company
3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Breakdown Data by Company
3.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Company (2018-2023)
3.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company (2018-2023)
3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Company (2018-2023)
3.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2018-2023)
3.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company (2018-2023)
3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Company
3.4 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Product Location Distribution
3.4.2 Players Renin-Angiotensin-System (RAS)-Acting Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region
4.1 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Geographic Region (2018-2023)
4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country/Region (2018-2023)
4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Country/Region (2018-2023)
4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Country/Region (2018-2023)
4.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth
4.4 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth
4.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth
4.6 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth
5 Americas
5.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country
5.1.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023)
5.1.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023)
5.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
5.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
6.1.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2018-2023)
6.1.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2018-2023)
6.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
6.3 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent by Country
7.1.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023)
7.1.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023)
7.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
7.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent by Country
8.1.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023)
8.1.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023)
8.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
8.3 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Renin-Angiotensin-System (RAS)-Acting Agent
10.3 Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting Agent
10.4 Industry Chain Structure of Renin-Angiotensin-System (RAS)-Acting Agent
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
11.3 Renin-Angiotensin-System (RAS)-Acting Agent Customer
12 World Forecast Review for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region
12.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Region
12.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Region (2024-2029)
12.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Type
12.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Application
13 Key Players Analysis
13.1 Novartis AG
13.1.1 Novartis AG Company Information
13.1.2 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis AG Main Business Overview
13.1.5 Novartis AG Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 AstraZeneca plc
13.3.1 AstraZeneca plc Company Information
13.3.2 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca plc Main Business Overview
13.3.5 AstraZeneca plc Latest Developments
13.4 Merck & Co., Inc.
13.4.1 Merck & Co., Inc. Company Information
13.4.2 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck & Co., Inc. Main Business Overview
13.4.5 Merck & Co., Inc. Latest Developments
13.5 Sanofi S.A.
13.5.1 Sanofi S.A. Company Information
13.5.2 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi S.A. Main Business Overview
13.5.5 Sanofi S.A. Latest Developments
13.6 Bristol-Myers Squibb Company
13.6.1 Bristol-Myers Squibb Company Company Information
13.6.2 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Company Main Business Overview
13.6.5 Bristol-Myers Squibb Company Latest Developments
13.7 Daiichi Sankyo Company,Limited
13.7.1 Daiichi Sankyo Company,Limited Company Information
13.7.2 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Daiichi Sankyo Company,Limited Main Business Overview
13.7.5 Daiichi Sankyo Company,Limited Latest Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Takeda Pharmaceutical Company Limited Company Information
13.8.2 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.8.5 Takeda Pharmaceutical Company Limited Latest Developments
13.9 Boehringer lngelheim GmbH
13.9.1 Boehringer lngelheim GmbH Company Information
13.9.2 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.9.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Boehringer lngelheim GmbH Main Business Overview
13.9.5 Boehringer lngelheim GmbH Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
13.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Angiotensin Converting Enzyme Inhibitors (ACEi)
Table 4. Major Players of Angiotensin Receptor Blockers (ARBs)
Table 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2018-2023) & (K Units)
Table 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
Table 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2018-2023) & ($ million)
Table 8. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2018-2023)
Table 9. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2018-2023) & (K Units)
Table 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2018-2023)
Table 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2018-2023)
Table 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2018-2023)
Table 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Company (2018-2023) & (K Units)
Table 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company (2018-2023)
Table 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company (2018-2023)
Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Producing Area Distribution and Sales Area
Table 21. Players Renin-Angiotensin-System (RAS)-Acting Agent Products Offered
Table 22. Renin-Angiotensin-System (RAS)-Acting Agent Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share Geographic Region (2018-2023)
Table 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country/Region (2018-2023)
Table 31. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023) & (K Units)
Table 34. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2018-2023)
Table 35. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2018-2023)
Table 37. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2018-2023) & (K Units)
Table 38. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2018-2023) & (K Units)
Table 39. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2018-2023) & (K Units)
Table 40. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2018-2023)
Table 41. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2018-2023)
Table 43. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2018-2023) & (K Units)
Table 44. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2018-2023) & (K Units)
Table 45. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023) & (K Units)
Table 46. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2018-2023)
Table 47. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2018-2023)
Table 49. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2018-2023) & (K Units)
Table 50. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Renin-Angiotensin-System (RAS)-Acting Agent
Table 58. Key Market Challenges & Risks of Renin-Angiotensin-System (RAS)-Acting Agent
Table 59. Key Industry Trends of Renin-Angiotensin-System (RAS)-Acting Agent
Table 60. Renin-Angiotensin-System (RAS)-Acting Agent Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List
Table 63. Renin-Angiotensin-System (RAS)-Acting Agent Customer List
Table 64. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Novartis AG Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 80. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Novartis AG Main Business
Table 82. Novartis AG Latest Developments
Table 83. Pfizer, Inc. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 84. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 85. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Pfizer, Inc. Main Business
Table 87. Pfizer, Inc. Latest Developments
Table 88. AstraZeneca plc Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 89. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 90. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. AstraZeneca plc Main Business
Table 92. AstraZeneca plc Latest Developments
Table 93. Merck & Co., Inc. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 95. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Merck & Co., Inc. Main Business
Table 97. Merck & Co., Inc. Latest Developments
Table 98. Sanofi S.A. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 100. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Sanofi S.A. Main Business
Table 102. Sanofi S.A. Latest Developments
Table 103. Bristol-Myers Squibb Company Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 104. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 105. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Bristol-Myers Squibb Company Main Business
Table 107. Bristol-Myers Squibb Company Latest Developments
Table 108. Daiichi Sankyo Company,Limited Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 109. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 110. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Daiichi Sankyo Company,Limited Main Business
Table 112. Daiichi Sankyo Company,Limited Latest Developments
Table 113. Takeda Pharmaceutical Company Limited Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 114. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 115. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Takeda Pharmaceutical Company Limited Main Business
Table 117. Takeda Pharmaceutical Company Limited Latest Developments
Table 118. Boehringer lngelheim GmbH Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 119. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 120. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Boehringer lngelheim GmbH Main Business
Table 122. Boehringer lngelheim GmbH Latest Developments
Table 123. Johnson & Johnson Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors
Table 124. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications
Table 125. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Johnson & Johnson Main Business
Table 127. Johnson & Johnson Latest Developments
List of Figures
Figure 1. Picture of Renin-Angiotensin-System (RAS)-Acting Agent
Figure 2. Renin-Angiotensin-System (RAS)-Acting Agent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Angiotensin Converting Enzyme Inhibitors (ACEi)
Figure 10. Product Picture of Angiotensin Receptor Blockers (ARBs)
Figure 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type in 2022
Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2018-2023)
Figure 13. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Hypertension
Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Hypertension (2018-2023) & (K Units)
Figure 15. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Heart Failure
Figure 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Heart Failure (2018-2023) & (K Units)
Figure 17. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Chronic Kidney Disease
Figure 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Chronic Kidney Disease (2018-2023) & (K Units)
Figure 19. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Other
Figure 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Other (2018-2023) & (K Units)
Figure 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2022)
Figure 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application in 2022
Figure 23. Renin-Angiotensin-System (RAS)-Acting Agent Sales Market by Company in 2022 (K Units)
Figure 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company in 2022
Figure 25. Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company in 2022
Figure 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales 2018-2023 (K Units)
Figure 30. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2018-2023 ($ Millions)
Figure 31. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales 2018-2023 (K Units)
Figure 32. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2018-2023 ($ Millions)
Figure 33. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales 2018-2023 (K Units)
Figure 34. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2018-2023 ($ Millions)
Figure 37. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country in 2022
Figure 38. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country in 2022
Figure 39. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
Figure 40. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2018-2023)
Figure 41. United States Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region in 2022
Figure 46. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Regions in 2022
Figure 47. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
Figure 48. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2018-2023)
Figure 49. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country in 2022
Figure 57. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country in 2022
Figure 58. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
Figure 59. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2018-2023)
Figure 60. Germany Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2018-2023)
Figure 69. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Renin-Angiotensin-System (RAS)-Acting Agent in 2022
Figure 75. Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting Agent
Figure 76. Industry Chain Structure of Renin-Angiotensin-System (RAS)-Acting Agent
Figure 77. Channels of Distribution
Figure 78. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Forecast by Region (2024-2029)
Figure 79. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界のレニン-アンジオテンシン-システム（RAS）作用剤市場予測 2023年-2029年] (コード：LP23DC04154)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のレニン-アンジオテンシン-システム（RAS）作用剤市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のバルブ遠隔制御（VRC）装置市場2022年：油圧バルブ遠隔制御（VRC）システム、空気圧バルブ遠隔制御（VRC）システム、電気バルブ遠隔制御（VRC）システム、その他
  • 世界の逆相カラム市場予測2023-2029：プレパックカラム-ガスクロマトグラフィー（Gc）システム、空カラム-ガスクロマトグラフィー（Gc）システム
  • 農機具用ゴムクローラのグローバル市場2023年：CTS（コンバージョン トラック システム）、TTS（トレーリング トラック システム）
  • 世界のパワーハードウェアインザループ市場2022年：システム、サービス
  • 世界の船舶におけるエネルギー効率化市場予測2023-2029：ソフトウェア&システム、省エネルギー機器

    • ◆H&Iグローバルリサーチのお客様（例）◆